These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35044469)

  • 41. Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors.
    Satapathy S; Mittal BR; Sood A; Sood A; Kapoor R; Gupta R
    Clin Nucl Med; 2020 Sep; 45(9):e393-e399. PubMed ID: 32604121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
    Kalshetty A; Ramaswamy A; Ostwal V; Basu S
    Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
    Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
    Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PRRT genomic signature in blood for prediction of
    Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study.
    Black JRM; Atkinson SR; Singh A; Evans J; Sharma R
    J Clin Endocrinol Metab; 2019 Feb; 104(2):285-292. PubMed ID: 30219888
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of
    Abou Jokh Casas E; Pubul Núñez V; Anido-Herranz U; Del Carmen Mallón Araujo M; Del Carmen Pombo Pasín M; Garrido Pumar M; Cabezas Agrícola JM; Cameselle-Teijeiro JM; Hilal A; Ruibal Morell Á
    World J Gastroenterol; 2020 Apr; 26(13):1513-1524. PubMed ID: 32308351
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
    Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
    Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; de Herder WW; Feelders RA; Krenning EP; Kwekkeboom DJ
    Endocr Relat Cancer; 2017 May; 24(5):243-251. PubMed ID: 28320783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
    Liu Q; Kulkarni HR; Zhao T; Schuchardt C; Chen X; Zhu Z; Zhang J; Baum RP
    Clin Nucl Med; 2023 Mar; 48(3):221-227. PubMed ID: 36723881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?
    Kunikowska J; Królicki L; Hubalewska-Dydejczyk A; Mikołajczak R; Sowa-Staszczak A; Pawlak D
    Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1788-97. PubMed ID: 21553086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors.
    Halperin R; Tirosh A
    JCO Oncol Pract; 2024 Oct; 20(10):1401-1409. PubMed ID: 38935916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience.
    Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B
    PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours.
    Alsadik S; Yusuf S; Al-Nahhas A
    Curr Radiopharm; 2019; 12(2):126-134. PubMed ID: 30714538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of
    Medaer E; Verslype C; Van Cutsem E; Dekervel J; Clement PM; Nackaerts K; Laenen A; Gheysens O; Goffin K; Jentjens S; Van Laere K; Deroose CM
    Acta Oncol; 2020 Jun; 59(6):644-651. PubMed ID: 32036716
    [No Abstract]   [Full Text] [Related]  

  • 60. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.